Exploring the Therapeutic Potential of Royal Jelly in Metabolic Disorders and Gastrointestinal Diseases
Nutrients · 2024
DOI: 10.3390/nu16030393 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, 2024. Verfasst von Hesham R El-Seedi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacognosy Group, Department of Pharmaceutical Biosciences, Uppsala University, Biomedical Centre, P.O. Box 591, SE-751 24 Uppsala, Sweden. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Gastrointestinal Diseases, Metabolic Diseases, Cardiovascular Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic disorders, encompassing diabetes mellitus, cardiovascular diseases, gastrointestinal disorders, etc., pose a substantial global health threat, with rising morbidity and mortality rates. Addressing these disorders is crucial, as conventional drugs often come with high costs and adverse effects. This review explores the potential of royal jelly (RJ), a natural bee product rich in bioactive components, as an alternative strategy for managing metabolic diseases. RJ exhibits diverse therapeutic properties, including antimicrobial, estrogen-like, anti-inflammatory, hypotensive, anticancer, and antioxidant effects. This review’s focus is on investigating how RJ and its components impact conditions like diabetes mellitus, cardiovascular disease, and gastrointestinal illnesses. Evidence suggests that RJ serves as a complementary treatment for various health issues, notably demonstrating cholesterol- and glucose-lowering effects in diabetic rats. Specific RJ-derived metabolites, such as 10-hydroxy-2-decenoic acid (10-HDA), also known as the “Queen bee acid,” show promise in reducing insulin resistance and hyperglycemia. Recent research highlights RJ’s role in modulating immune responses, enhancing anti-inflammatory cytokines, and suppressing key inflammatory mediators. Despite these promising findings, further research is needed to comprehensively understand the mechanisms underlying RJ’s therapeutic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacognosy Group, Department of Pharmaceutical Biosciences, Uppsala University, Biomedical Centre, P.O. Box 591, SE-751 24 Uppsala, Sweden.
- School of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China.
- International Joint Research Laboratory of Intelligent Agriculture and Agri-Products Processing, Jiangsu University, Zhenjiang 210024, China.
- Indigenous Knowledge and Heritage Center, Ghibaish College of Science and Technology, Ghibaish 51111, Sudan.
- Department of Bee Research, Plant Protection Research Institute, Agricultural Research Centre, Giza 12627, Egypt.
- Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Naples, Italy.
ORCID-Profile: Hesham R El-Seedi, Suzy Salama, Aida A Abd El-Wahed, Zhiming Guo, Alessandro Di Minno, Maria Daglia, Chuan Li, Kai Wang
Zitieren
APA
El-Seedi, H. R., Salama, S., El-Wahed, A. A. A., Guo, Z., Di Minno, A., Daglia, M., Li, C., Guan, X., Buccato, D. G., Khalifa, S. A. M., & Wang, K. (2024). Exploring the Therapeutic Potential of Royal Jelly in Metabolic Disorders and Gastrointestinal Diseases. Nutrients. https://doi.org/10.3390/nu16030393
Vancouver
El-Seedi HR, Salama S, El-Wahed AAA, Guo Z, Di Minno A, Daglia M, et al. Exploring the Therapeutic Potential of Royal Jelly in Metabolic Disorders and Gastrointestinal Diseases. Nutrients. 2024. doi:10.3390/nu16030393
BibTeX
@article{ElSeedi2024,
author = {El-Seedi, Hesham R and Salama, Suzy and El-Wahed, Aida A Abd and Guo, Zhiming and Di Minno, Alessandro and Daglia, Maria and Li, Chuan and Guan, Xiao and Buccato, Daniele Giuseppe and Khalifa, Shaden A M and Wang, Kai},
title = {Exploring the Therapeutic Potential of Royal Jelly in Metabolic Disorders and Gastrointestinal Diseases},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16030393}
}
EUVIMED